Clinical trials in Salzburg – page 3

285 clinical trials in Salzburg, Austria across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Salzburg at a glance

285

clinical trials

Research sites4

Quick filters

285 trials in Salzburg

Open in trial search

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Ruxolitinib
Sponsor:Novartis Pharma AG

Contact Research Centre

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Guselkumab
Sponsor:Janssen Cilag International

Contact Research Centre

Colorectal cancer metastatic

Recruiting

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Incyte Corp.

Contact Research Centre

Type 2 diabetes mellitus+1

Recruiting

A study on the effectiveness of cagrilintide and semaglutide for weight management in children and adolescents with obesity

Investigational

A study on the effectiveness of cagrilintide and semaglutide for weight management in children and adolescents with obesity

Investigational

Austria

Participants:0–17 years
Substances:Cagrilintide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Breast cancer+4

Recruiting

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Elacestrant
Sponsor:WSG Women's Cancer Study Group GmbH

Contact Research Centre

Colorectal cancer metastatic

Recruiting

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Breast cancer metastatic

Recruiting

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Letrozole
Sponsor:Olema Pharmaceuticals Inc.

Contact Research Centre

Proctitis

Recruiting

Study of budesonide suppositories to treat acute radiation proctitis in men with prostate cancer

Registered drug

Study of budesonide suppositories to treat acute radiation proctitis in men with prostate cancer

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Budesonide
Sponsor:Dr. Falk Pharma GmbH

Contact Research Centre

Metabolic dysfunction-associated liver disease

Recruiting

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:LY3437943 sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Neovascular age-related macular degeneration

Recruiting

Study of Surabgene Lomparvovec Compared to Ranibizumab for Adults with Wet Age-Related Macular Degeneration

Registered drugNo placebo

Study of Surabgene Lomparvovec Compared to Ranibizumab for Adults with Wet Age-Related Macular Degeneration

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Ranibizumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

B-cell type acute leukaemia

Recruiting

Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

Registered drugNo placebo

Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

Registered drugNo placebo

Austria

Participants:0–17 years · 18–64 years
Substances:Blinatumomab
Sponsor:Universita Degli Studi Di Milano Bicocca

Contact Research Centre

Cervix carcinoma

Recruiting

A Study of Sacituzumab Tirumotecan, Pembrolizumab, and Bevacizumab for Patients with Metastatic Cervical Cancer That Has Spread or Returned

Registered drugNo placebo

A Study of Sacituzumab Tirumotecan, Pembrolizumab, and Bevacizumab for Patients with Metastatic Cervical Cancer That Has Spread or Returned

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Other cities in Austria

The busiest research cities in the country

All 47 cities in Austria

Clinical research in Salzburg

What the registry says about research in the country

01 Oncology Research

Comprehensive studies focusing on metastatic cancers and innovative treatment approaches, including trials investigating new therapies for prostate cancer, colorectal cancer, and bladder cancer.

Advanced cancer treatments
Immunotherapy combinations
Novel therapeutic agents

Multiple clinical trials evaluating targeted therapies and combination treatments for various stages of cancer progression.

02 Hematological Studies

Investigating breakthrough treatments for multiple myeloma and acute myeloid leukemia, with emphasis on innovative therapeutic combinations and targeted approaches.

Blood cancer therapies
Novel drug combinations
Treatment resistance studies

Focus on improving outcomes for patients with various blood disorders through advanced therapeutic strategies.

03 Chronic Disease Management

Research initiatives addressing cardiovascular disease, Crohn's disease, and Alzheimer's disease, exploring new treatment modalities and therapeutic approaches.

Inflammatory conditions
Cardiovascular health
Neurological disorders

Comprehensive studies aimed at developing more effective treatments for chronic conditions affecting quality of life.

Back to Austria All countries

Clinical trials in Salzburg – page 3

285 trials in Salzburg

Myelofibrosis+1

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Crohn's disease

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Colorectal cancer metastatic

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Type 2 diabetes mellitus+1

A study on the effectiveness of cagrilintide and semaglutide for weight management in children and adolescents with obesity

Breast cancer+4

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Colorectal cancer metastatic

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Breast cancer metastatic

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Proctitis

Study of budesonide suppositories to treat acute radiation proctitis in men with prostate cancer

Metabolic dysfunction-associated liver disease

Neovascular age-related macular degeneration

Study of Surabgene Lomparvovec Compared to Ranibizumab for Adults with Wet Age-Related Macular Degeneration

B-cell type acute leukaemia

Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

Cervix carcinoma

A Study of Sacituzumab Tirumotecan, Pembrolizumab, and Bevacizumab for Patients with Metastatic Cervical Cancer That Has Spread or Returned

Filter the trials

Other cities in Austria

Clinical research in Salzburg

Prefer not to search? Our Concierge searches the trials for you.